

## Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera

Yfat Yahalom-Ronen, Noam Erez, Morly Fisher, Hadas Tamir, Boaz Politi, Hagit Achdout, Sharon Melamed, Itai Glinert, Shay Weiss, Inbar Cohen-Gihon, Ofir Israeli, Marina Izak, Michal Mandelboim, Yoseph Caraco, Noa Madar-Balakirski, Adva Mechaly, Eilat Shinar, Daniel Cohen, Adi Beth-Din, Anat Zvi, Hadar Marcus, Tomer Israely\*, Nir Paran\*

\*Corresponding authors

### **Abstract:**

BriLife® (rVSV-ΔG-spike) is a SARS-CoV-2 vaccine candidate based on vesicular stomatitis virus (VSV) platform. We show that sera from BriLife® vaccinees maintain neutralization capacity against alpha, beta, gamma and delta SARS-CoV-2 variants. BriLife® spontaneously-acquired spike mutations, corresponding with key SARS-CoV-2 variants' mutations, may contribute to its efficacy against SARS-CoV-2 variants.

BriLife® is a recombinant replication-competent Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) vaccine candidate, based on the Vesicular Stomatitis Virus (VSV) platform, in which the VSV glycoprotein (G) was replaced by the SARS-CoV-2 spike protein (S) to make an rVSV-ΔG-spike [1].

Since the emergence of the original SARS-CoV-2, several variants have been described, including variants that appeared in the United Kingdom (alpha or B.1.1.7), South Africa (beta or B.1.351), Brazil (gamma or P.1), and India (delta or B.1.617.2) (<https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>). The emergence of SARS-CoV-2 variants presents a challenge to the ability of vaccines to provide proper immune response.

We tested blinded serum samples from two cohorts of participants in a BriLife® phase II clinical trial (ClinicalTrials.gov - NCT04608305) two weeks following intramuscular prime-boost vaccination for their ability to neutralize SARS-CoV-2 variants alpha, beta, gamma or delta. Inclusion criteria were negative SARS-CoV-2 nucleocapsid binding (data not shown) and positive SARS-CoV-2 neutralization response against the original virus.

Nine tested sera (“cohort 1”, Table S1) efficiently neutralized the original virus, as well as the gamma variant, with mean titers of 246 and 357, respectively (0.7-fold change, Fig. 1c, Table S1). Nearly all tested sera neutralized alpha (8/9 samples) and beta (7/9 samples) variants, with mean titers of 163 and 103, respectively (1.5-fold reduction relative to original virus, and 2.4-fold reduction, Fig. 1a-b, Table S1).

In recent months, delta variant of concern (VOC) has become dominant worldwide exhibiting increased transmissibility, apparent immune escape [2], and breakthrough infections in vaccinated individuals [3]. We therefore tested another set of 11 vaccinees sera (“cohort 2”, Table S2) for neutralization of both original virus and delta VOC. Of 11 tested sera which neutralized the original virus, ten also neutralized the delta variant, with no significant difference in neutralization titers (Fig. 1d, Table S2).

Immunity to surface antigens of viral vectored-based vaccines (e.g. adenovirus-based platforms) might hamper their efficacy upon repeated usage. Replacement of VSV-G surface antigen with the antigen of interest reduces the risk of vector immunity [4]. We

show that vector immunity was not significantly induced following BriLife® vaccination (Fig. 1e, Table S3), excluding the risk of reduced vaccine efficacy upon repeated vaccinations.

We also compared neutralization capacity of 9 convalescent sera from early pandemic infections (“cohort 3”, Table S4) between the original virus and alpha, beta, gamma or delta variants. We show no significant difference in neutralization titers of the original virus and that of alpha, beta or gamma variants (Fig. 2a-c, Table S4). However, we do see a significant 3.8-fold reduction in neutralization titers of convalescent sera against delta VOC compared to the original virus (Fig. 2d, Table S4).

Amino acid substitutions in SARS-CoV-2 emerging variants might compromise the protection afforded by vaccines and therapeutic antibodies. Currently approved vaccines use a modified version of the spike sequence of the original Wuhan virus [5-7]. Convalescent sera tested in the current study was obtained from individuals infected at early stages of the pandemic, hence exposed to the original virus.

Development of BriLife® was accompanied by spontaneous acquisition of several mutations, some of which are at the spike protein at sites of major importance to antibody-mediated immunity, such as N501 and E484 located in the receptor binding domain (RBD) [1]. An additional mutation is R685G at the RRAR multibasic furin cleavage site, located at the junction of the receptor-binding (S1) and fusion (S2) domains of the spike protein [1]. With that mentioned, final vaccine batches are genetically stable. BriLife® above-mentioned mutations are similar or identical to some of the key naturally-occurring mutations in SARS-CoV-2 variants. The N501Y substitution is found in alpha, beta and gamma variants [8]. E484 is mutated in BriLife® to aspartic acid to form E484D. In beta and gamma variants, E484 is mutated to Lysine (K, E484K). E484K, E484D, E484A and E484G substitutions were shown to escape neutralization by convalescent human sera [8], further consolidating the role of E484 in antibody binding. N501Y as a single mutation does not significantly impair sensitivity to vaccine-induced antibodies [9]. However, combination of E484K, N501Y and additional mutations such as K417N or K417T found in beta and gamma variants, respectively, was shown to significantly affect neutralization capacity in sera of convalescent or vaccinated individuals [10]. We suggest that the

aforementioned BriLife® mutations might provide an advantage in combating SARS-CoV-2 variants.

As for the furin cleavage site, the leading proline residue P681 located just before the RRAR multibasic motif is replaced by Histidine at alpha variant (P681H) and by Arginine in delta variant (P681R). This region is of major importance to transmissibility and spreading of SARS-CoV-2 [8]. Whether the spontaneously acquired R685G mutation of BriLife® have a beneficial effect on vaccine efficacy, specifically against alpha and delta, awaits further investigation.


There is a major concern regarding the ability of vaccines to protect against SARS-CoV-2 variants. Neutralization titers against variants following two-dose vaccination with BNT162b2, mRNA-1273 or ChAdOx1 nCoV-19 were reported, showing for most only a minor reduction in alpha neutralization, but a strong reduction in beta and gamma neutralization [11], while others report no significant reduction in vaccine efficacy against the gamma variant [10, 12, 13]. An overall reduction in neutralization potential has been reported against the beta variant ranging between ~2-30-fold, depending on the report [8, 10, 13, 14]. For delta variant, some report a modest reduction in the effectiveness of two-dose vaccines compared to the alpha variant or to the original virus. An overall reduction ranges between ~2-11 fold [12-15].

A significant reduction in neutralization potential of convalescent sera from early pandemic stages against alpha, beta, gamma or delta variants was also reported [11, 13, 16-18]. Overall, it appears that the beta is the most resistant variant to neutralization either by convalescent sera, currently available vaccines, or BriLife® vaccination. Recent cross-neutralization data from convalescent sera from different pandemic waves shed light on the possible contribution of specific Spike mutations to protection from variants [11] and raise the need for updated vaccines. Limitation of this brief report is the relatively small number of serum samples tested.


We suggest that spontaneously-acquired mutations such as N501Y and E484D, that occurred during BriLife® development and correspond to naturally-occurring mutations of

SARS-CoV-2 variants, may increase the potential of BriLife® to maintain effectiveness against current SARS-CoV-2 variants, and potentially against future VOC.

Taken together, our data indicates that BriLife®-induced antibodies maintain neutralizing potential against all tested variants, and most importantly against the delta VOC.



**Figure 1: Neutralization of alpha, beta, gamma and delta variants, or WT-VSV, by sera from BriLife®-vaccinated human participants:** Neutralization titers (NT<sub>50</sub>) of BriLife® participants' sera (following boost vaccination) against SARS-CoV-2 original virus, compared to (a) alpha, (b) beta, (c) gamma (n=9), and (d) delta (n=11) variants. Each serum is color coded for all tested viruses. Significance was determined by unpaired t-test. p values: 0.4088, 0.0498, 0.2528, 0.9494, for comparison of original virus to alpha, beta, gamma and delta, respectively. (e) Neutralization titers (NT<sub>50</sub>) against rVSV-WT in sera samples of 10 vaccinees collected at time zero (T0), 28 days post 1<sup>st</sup> vaccination (P) and two weeks following 2<sup>nd</sup> vaccination (P+B). Sera samples are color coded. LOD-limit of detection (LOD=20). Samples below LOD were assigned a value of 10 (half of the LOD). Statistical significance was determined by one-way ANOVA nonparametric test with Kruskal–Wallis test. Data is presented as mean ± SEM.



**Figure 2: Neutralization of alpha, beta, gamma and delta variants by sera from convalescent patients:** Neutralization titers (NT<sub>50</sub>) of convalescent patients' sera against SARS-CoV-2 original virus, in comparison to (a) alpha, (b) beta, (c) gamma and (d) delta (n=9) variants. Each serum is color coded for all tested viruses. LOD is indicated in each panel (a, c LOD=40, b, d LOD=20). Samples below LOD were assigned a value of half the LOD. Data is presented as mean ± SEM. Significance was determined by unpaired t-test. p values: 0.2454, 0.1514, 0.4184, 0.0409, for comparison of original virus to alpha, beta, gamma and delta, respectively.

## Extended data

### **Acknowledgements:**

We thank the participants in BriLife® clinical trial for their altruism and their dedication to this trial. We thank Prof. Yoseph Caraco from Hadassah Medical Center (Jerusalem), Dr. Eytan Ben-Ami from Sheba Medical Center (Ramat Gan), Dr. Avivit Peer from Rambam Health Care Campus (Haifa), Prof. David Zeltser from Tel Aviv Sourasky Medical Center (Tel Aviv), Prof. Shlomo Maayan from Barzilai Medical Center (Ashkelon), Dr. Victor Vishlitzky from Meir Medical Center (Kefar Sava), Dr. Tal Brosh from Assuta (Ashdod), Dr. Noa Eliakim from Rabin Medical Center (Petah Tiqwa), and the respective Clinical Center teams in Israel participating in this study. We also acknowledge the contributions of the IIBR20-001 Clinical Trial Group at IIBR, Gsap (Haifa, Israel) and IQVIA (Durham NC, USA).

SARS-CoV-2 original virus was kindly provided by Bundeswehr Institute of Microbiology, Munich, Germany. SARS-CoV-2 variants alpha, beta, gamma and delta were kindly provided by Prof. Ella Mendelson, Dr. Itai Nemet and Limor Kliker from the Central Virology Lab of the Israel Ministry of Health. rVSV-WT was kindly provided by Prof. Eran Bacharach from Tel Aviv University.

**Table S1.** Neutralizing titers (NT<sub>50</sub>) of BriLife® vaccinees against SARS-CoV-2 original virus, variants alpha, beta, and gamma (cohort 1). Samples that were below LOD were assigned a value of 10 (half of the LOD).

<b>Vaccinee #</b>	<b>original virus</b>	<b>alpha</b>	<b>beta</b>	<b>gamma</b>
1	241	72	10	321
2	65	10	44	114
3	137	54	10	160
4	197	154	75	228
5	251	108	34	504
6	220	49	41	426
7	240	86	234	349
8	258	95	60	220
9	608	836	420	896
<b>Mean titer</b>	<b>246</b>	<b>163</b>	<b>103</b>	<b>357</b>
Fold change (relative to original virus)		1.5	2.4	0.7



**Table S2.** Neutralization titers (NT<sub>50</sub>) of BriLife® vaccinees against SARS-CoV-2 original virus and delta variant of concern (cohort 2). Samples that were below LOD were assigned a value of 10 (half of the LOD).

<b>Vaccinee #</b>	<b>original virus</b>	<b>delta</b>
1	41	38
2	39	70
3	23	21
4	61	10
5	190	109
6	54	110
7	71	33
8	29	31
9	112	214
10	69	92
11	93	38
<b>Mean titers</b>	<b>71</b>	<b>69</b>
Fold change (relative to original virus)		1

**Table S3.** Neutralization titers (NT<sub>50</sub>) of BriLife® vaccinees against rVSV-WT (Indiana serotype) at time zero (T0), 28 days post 1<sup>st</sup> vaccination (P) and two weeks following 2<sup>nd</sup> vaccination (P+B). Samples that were below LOD were assigned a value of 10 (half of the LOD).

<b>Vaccinee #</b>	<b>T0</b>	<b>P</b>	<b>P+B</b>
1	21	38	62
2	83	99	202
3	10	10	72
4	10	10	10
5	115	57	52
6	10	45	10
7	10	10	10
8	43	30	45
9	10	10	59
10	10	10	10
<b>Mean titers</b>	<b>32</b>	<b>32</b>	<b>53</b>

**Table S4.** Neutralizing titers (NT<sub>50</sub>) of convalescent sera against SARS-CoV-2 original virus, variants alpha, beta, gamma and delta (cohort 3). Samples that were below LOD were assigned a value of half of the LOD.

<b>Convalescent sera #</b>	<b>original virus</b>	<b>alpha</b>	<b>beta</b>	<b>gamma</b>	<b>delta</b>
1	541	296	279	423	85
2	1385	1027	760	953	212
3	758	197	139	333	160
4	142	177	160	95	79
5	366	100	107	297	178
6	323	40	79	269	115
7	119	41	65	132	39
8	104	20	66	40	103
9	123	51	39	50	41
<b>Mean titers</b>	<b>429</b>	<b>216</b>	<b>188</b>	<b>288</b>	<b>113</b>
Fold change (relative to original virus)		2.0	2.3	1.5	3.8

## **Methods:**

### **Samples:**

Serum samples of BriLife® vaccinees were obtained from participants in a randomized, multi-center, placebo-controlled, dose-escalation phase II of an ongoing clinical trial, aimed to evaluate the safety, immunogenicity and potential efficacy of BriLife®, an rVSV-SARS-CoV-2-S vaccine (IIBR-100) in Adults (ClinicalTrials.gov - NCT04608305). All participants were vaccinated intramuscularly in a prime-boost regimen (28 days apart) and samples were obtained approximately two weeks following boost vaccination.

This study was performed in compliance with International Council for Harmonisation (ICH) Good Clinical Practices (GCP), including the archiving of essential documents as well as the ethical principles of the Declaration of Helsinki.

Serum samples of convalescent COVID-19 patients were collected by the National Blood Services of “Magen David Adom” in Israel within a protocol for plasma donation. All convalescent volunteers gave their informed consent to the National Blood services of Magen David Adom. The study was approved by the ethics committee of the Israeli Ministry of Health (0083-20-WOMC)[20].

### **Cells:**

Vero clone E6 cells (Vero E6, ATCC CRL-1586™) were grown in growth medium [Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS), MEM nonessential amino acids (NEAA), 2 mM L-glutamine, 100 Units/ml penicillin, 0.1 mg/ml streptomycin, 12.5 Units/ml nystatin (P/S/N), all from Biological Industries, Israel]. Calu3 cells (ATCC HTB-55) were grown in growth medium RPMI supplemented with 10% fetal bovine serum (FBS), MEM non-essential amino acids, 2 mM L-glutamine, 100 units per ml penicillin and 1% Na-pyruvate. Cells were cultured at 37 °C, 5% CO<sub>2</sub> with 95% humidity.

### **Viruses:**

Virus stocks of SARS-CoV-2 original virus (GISAID accession EPI\_ISL\_406862) were propagated (four passages) in Vero E6 cells. SARS-CoV-2 variants were provided by the Central Virology Lab of the Israel Ministry of health [15]. Alpha variant (B.1.1.7, GISAID

accession EPI\_ISL\_4169857) was passaged once in Vero E6 cells, followed by two passages in Calu3 cells. Beta (B.1.351, GISAID accession EPI\_ISL\_4169885), gamma (P.1, GISAID accession EPI\_ISL\_4169886) and delta (B.1.617.2, GISAID accession EPI\_ISL\_4169986) variants were propagated in Vero E6 cells. Each variant was confirmed by next-generation sequencing (NGS). Recombinant Vesicular Stomatitis Virus Indiana serotype (rVSV-WT) was propagated in Vero cells [1].

All virus stocks were tittered on Vero E6 cells by plaque assay as previously described [1]. Handling and working with SARS-CoV-2 virus were conducted in a BSL3 facility in accordance with the biosafety guidelines of the Israel Institute for Biological Research (IIBR).

#### Plaque reduction neutralization test (PRNT<sub>50</sub>):

Vero E6 cells were seeded in 12-well plates. Sera from BriLife® vaccinees or COVID-19 convalescent patients were heat inactivated (HI) (56 °C for 30 min), then diluted in twofold serial dilutions (between 1:20 and 1:1280) in 300 µl of infection medium, mixed with 300 µl of either 300 pfu/ml of SARS-CoV-2 original virus, each variant (alpha, beta, gamma or delta), or rVSV-WT, and incubated at 37 °C, 5% CO<sub>2</sub> for 1 h. Serum-virus mixtures were added in duplicates to the cells for 1 h at 37 °C. Virus samples (original virus, alpha, beta, gamma, delta variant, or rVSV-WT) without serum served as controls for each respective virus-serum mixture. Two milliliters overlay were added to each well and plates were incubated at 37 °C, 5% CO<sub>2</sub> for 24 h (for rVSV-WT), 72 h (for SARS-CoV-2 original virus, beta, gamma or delta variant) or 96 h (for alpha variant). Following incubation, overlay was aspirated and the cells were fixed and stained with 1 ml/well of crystal violet solution. The plaques in each well were numbered, and the serum dilution that neutralizes 50% of the virions (NT<sub>50</sub>) was calculated using GraphPad Prism 6 software (GraphPad Software Inc.).

#### Statistical analysis:

Data were analyzed with GraphPad Prism 6 software. Exact p values are provided for each analysis. Statistical significance for SARS-CoV-2 variants neutralization were determined by unpaired t-test, p values are indicated. Statistical significance for VSV vector immunity was determined by one-way ANOVA nonparametric test by Kruskal–Wallis test.

## **References:**

1. Yahalom-Ronen, Y., et al., *Nat Commun*, 2020. **11**(1): p. 6402.
2. Singh, J., et al., *Nat Med*, 2021. **27**(7): p. 1131-1133.
3. Levine-Tiefenbrun, M., et al., *medRxiv*, 2021: p. 2021.08.29.21262798.
4. Marzi, A., et al., *Emerg Infect Dis*, 2015. **21**(2): p. 305-7.
5. Baden, L.R., et al., *N Engl J Med*, 2021. **384**(5): p. 403-416.
6. Folegatti, P.M., et al., *Lancet*, 2020. **396**(10249): p. 467-478.
7. Polack, F.P., et al., *N Engl J Med*, 2020. **383**(27): p. 2603-2615.
8. Harvey, W.T., et al., *Nat Rev Microbiol*, 2021. **19**(7): p. 409-424.
9. Pegu, A., et al., *Science*, 2021. **373**(6561): p. 1372-1377.
10. Hoffmann, M., et al., *Cell*, 2021. **184**(9): p. 2384-2393 e12.
11. Liu, C., et al., *Cell*, 2021. **184**(16): p. 4220-4236 e13.
12. Davis, C., et al., *medRxiv*, 2021: p. 2021.06.23.21259327.
13. Planas, D., et al., *Nature*, 2021. **596**(7871): p. 276-280.
14. Noori, M., et al., *Rev Med Virol*, 2021: p. e2277.
15. Lustig, Y., et al., *Euro Surveill*, 2021. **26**(26).
16. Bates, T.A., et al., *Nat Commun*, 2021. **12**(1): p. 5135.
17. Wang, B., et al., *NPJ Vaccines*, 2021. **6**(1): p. 125.
18. Yue, S., et al., *Front Immunol*, 2021. **12**: p. 751584.
19. Dupont, L., et al., *Nat Microbiol*, 2021. **6**(11): p. 1433-1442.
20. Maor, Y., et al., *EClinicalMedicine*, 2020. **26**: p. 100525.